| Dr Stephen Andrew Lin, MD | |
|
36 West Yokuts Ave, Suite 1, Stockton, CA 95207-5713 | |
| (209) 952-3700 | |
| (209) 478-3302 |
| Full Name | Dr Stephen Andrew Lin |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 33 Years |
| Location | 36 West Yokuts Ave, Stockton, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073612735 | NPI | - | NPPES |
| 00G748090 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | G74809 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Valley Eye Medical Group Inc | 8729178843 | 8 |
News Archive
An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization.
A unique type of immune cell has been discovered in human breast tissue, and breast cancer patients with more of these cells are more likely to survive, finds new research from the Francis Crick Institute and King's College London.
Volunteering is known to provide health benefits to the person doing the volunteering. Now, a new study finds that older adults with functional limitations (trouble conducting daily tasks like cooking meals) in particular appear to reap the benefits from helping others.
Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.
Hythiam, Inc. (NASDAQ:HYTM) today announced that on August 28, 2009 Hythiam, Inc. (the "Company") received a letter (the "Staff Determination") from the Nasdaq Stock Market ("NASDAQ") notifying the Company that, based upon the Company's non-compliance with the $10 million stockholders' equity requirement set forth in NASDAQ Listing Rule 5450(b) as of August 27, 2009, the Company's securities were subject to delisting from The NASDAQ Global Market unless the Company requests a hearing before the NASDAQ Listing Qualifications Panel (the "NASDAQ Panel").
› Verified 8 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization.
A unique type of immune cell has been discovered in human breast tissue, and breast cancer patients with more of these cells are more likely to survive, finds new research from the Francis Crick Institute and King's College London.
Volunteering is known to provide health benefits to the person doing the volunteering. Now, a new study finds that older adults with functional limitations (trouble conducting daily tasks like cooking meals) in particular appear to reap the benefits from helping others.
Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.
Hythiam, Inc. (NASDAQ:HYTM) today announced that on August 28, 2009 Hythiam, Inc. (the "Company") received a letter (the "Staff Determination") from the Nasdaq Stock Market ("NASDAQ") notifying the Company that, based upon the Company's non-compliance with the $10 million stockholders' equity requirement set forth in NASDAQ Listing Rule 5450(b) as of August 27, 2009, the Company's securities were subject to delisting from The NASDAQ Global Market unless the Company requests a hearing before the NASDAQ Listing Qualifications Panel (the "NASDAQ Panel").
› Verified 8 days ago
| Entity Name | Central Valley Eye Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609975366 PECOS PAC ID: 8729178843 Enrollment ID: O20071213000153 |
News Archive
An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization.
A unique type of immune cell has been discovered in human breast tissue, and breast cancer patients with more of these cells are more likely to survive, finds new research from the Francis Crick Institute and King's College London.
Volunteering is known to provide health benefits to the person doing the volunteering. Now, a new study finds that older adults with functional limitations (trouble conducting daily tasks like cooking meals) in particular appear to reap the benefits from helping others.
Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.
Hythiam, Inc. (NASDAQ:HYTM) today announced that on August 28, 2009 Hythiam, Inc. (the "Company") received a letter (the "Staff Determination") from the Nasdaq Stock Market ("NASDAQ") notifying the Company that, based upon the Company's non-compliance with the $10 million stockholders' equity requirement set forth in NASDAQ Listing Rule 5450(b) as of August 27, 2009, the Company's securities were subject to delisting from The NASDAQ Global Market unless the Company requests a hearing before the NASDAQ Listing Qualifications Panel (the "NASDAQ Panel").
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen Andrew Lin, MD 36 West Yokuts Ave, Suite 1, Stockton, CA 95207-5713 Ph: (209) 952-3700 | Dr Stephen Andrew Lin, MD 36 West Yokuts Ave, Suite 1, Stockton, CA 95207-5713 Ph: (209) 952-3700 |
News Archive
An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization.
A unique type of immune cell has been discovered in human breast tissue, and breast cancer patients with more of these cells are more likely to survive, finds new research from the Francis Crick Institute and King's College London.
Volunteering is known to provide health benefits to the person doing the volunteering. Now, a new study finds that older adults with functional limitations (trouble conducting daily tasks like cooking meals) in particular appear to reap the benefits from helping others.
Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.
Hythiam, Inc. (NASDAQ:HYTM) today announced that on August 28, 2009 Hythiam, Inc. (the "Company") received a letter (the "Staff Determination") from the Nasdaq Stock Market ("NASDAQ") notifying the Company that, based upon the Company's non-compliance with the $10 million stockholders' equity requirement set forth in NASDAQ Listing Rule 5450(b) as of August 27, 2009, the Company's securities were subject to delisting from The NASDAQ Global Market unless the Company requests a hearing before the NASDAQ Listing Qualifications Panel (the "NASDAQ Panel").
› Verified 8 days ago
Dr. Charles Kim, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1899 W March Ln, Stockton, CA 95207 Phone: 209-623-4700 Fax: 209-623-4710 | |
Dr. Daniel Edward Levinsohn, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 1899 W March Ln, Stockton, CA 95207 Phone: 209-623-4706 Fax: 209-623-4716 | |
Dr. John C. Canzano, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 255 E Weber Ave, Stockton, CA 95202 Phone: 209-466-5566 Fax: 209-466-0535 | |
Josepha Mensah-adubofour, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 7373 West Ln, Stockton, CA 95210 Phone: 209-476-2000 | |
On-tat Lee, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1617 Saint Marks Plz Ste D, Stockton, CA 95207 Phone: 209-478-1797 Fax: 209-478-1224 | |
Dr. Robert Scott Foster, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 36 West Yokuts Ave, Ste 1, Stockton, CA 95207 Phone: 209-952-3700 Fax: 209-478-3302 |